THE USE OF VERAPAMIL IN INFANTS IS CONTROVERSIAL. THE POSSIBILITY OF IRREVERSIBLE SIDE EFFECTS (PROFOUND BRADYCARDIA AND HYPOTENSION) HAS LIMITED ITS USE.
- to control supraventricular tachycardia
- verapamil is a calcium-channel blocking agent
- exerts a negative chronotropic effect, depresses automaticity and conduction
- hypotension, bradycardia, 1st, 2nd, or 3rd degree A-V block
- may increase serum digoxin concentrations
- monitor heart rate and blood pressure continuously during administration of this drug
- use may be contraindicated in cases of congestive heart failure caused by hydrops
- 0.1 to 0.3 mg/kg (100 to 300 mcg/kg) IV push over 2 minutes, given by a physician only; this dose may be repeated in 30 minutes
- 2.5 mg/mL, 2 mL ampoule
- Cloherty JP and Stark AR (eds): Manual of Neonatal Intensive Care, Little, Brown and Company, 1991.
- Roberts, RJ: Drug Therapy in Infants, W.B. Saunders, Toronto, 1984.
- Gomella TL (Ed): Neonatology - Management, Procedures, On-Call Problems, Diseases, Drugs, 1992, Appleton and Lange, Norwalk, Connecticut.
- Taketomo CK, Hodding JH and Kraus DM: Pediatric Dosage Handbook, Lexi-Comp Inc., Cleveland, 1992.